儿童脊髓性肌萎缩症鞘内注射诺西那生钠的全面机构经验总结
回顾性分析本机构2017年3月至12月26例脊髓性肌萎缩症患儿共104次鞘内诺西那生钠注射,技术成功率100%;60次无术前影像经标准椎间隙入路完成,44次复杂病例需术前影像规划,分别采用标准椎间隙、椎间孔或颈椎穿刺入路,无即刻或长期并发症,仅1例出现短期脑膜刺激征和注射部位背痛;作者据此提出促进安全有效给药的流程算法。
要点
- 儿童脊髓性肌萎缩症合并神经肌肉性脊柱侧弯或脊柱内固定时,鞘内注射需术前影像规划并考虑替代入路。
- 本机构104次鞘内诺西那生钠注射技术成功率达100%,复杂病例可采用标准椎间隙、椎间孔或颈椎穿刺入路。
- 术后仅1例出现短期脑膜刺激征和注射部位背痛,无即刻或长期并发症。
核心结论
- 尽管本机构鞘内诺西那生钠给药技术成功率达100%,但实践在研究过程中不断演变,早期经验促使作者制定算法以促进不同SMA类型、脊柱解剖异常及复杂脊柱内固定患儿的安全有效给药。
研究设计与样本
- 单中心回顾性机构经验总结,纳入2017年3月至12月转诊接受鞘内诺西那生钠注射的26例脊髓性肌萎缩症患儿,共104次注射;部分脊柱内固定患儿术前申请脊柱影像规划,使用标准鞘内注射设备,所有患儿由转诊神经科医生随访。
诊断标准与关键数值
- 26例患儿共完成104次鞘内诺西那生钠注射,技术成功率为100%。
- 60次注射未行术前影像,经标准椎间隙技术完成。
- 44次复杂病例(神经肌肉性脊柱侧弯或脊柱内固定)注射中,19次经L2至S1标准椎间隙技术完成,22次经L3至L5椎间孔入路完成,3次经颈椎穿刺技术完成。
临床应用与阅片要点
- 对脊柱内固定的特定患儿可术前申请脊柱影像以辅助术前规划。
- 复杂病例可选标准椎间隙(L2至S1)、椎间孔(L3至L5)或颈椎穿刺入路完成鞘内注射。
- 作者基于早期经验制定算法以促进不同SMA类型、脊柱解剖异常及复杂脊柱内固定患儿的安全有效给药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Spinal muscular atrophy (SMA) is an autosomal-recessive neuromuscular disorder resulting in progressive muscle weakness. In December 2016, the U.S. Food and Drug Administration approved the first treatment for SMA, a drug named nusinersen (Spinraza) that is administered intrathecally. However many children with SMA have neuromuscular scoliosis or spinal instrumentation resulting in challenging intrathecal access. Therefore alternative routes must be considered in these complex patients.
OBJECTIVE: To investigate routes of drug access, we reviewed our institutional experience of administering intrathecal nusinersen in all children with spinal muscular atrophy regardless of spinal anatomy or instrumentation.
MATERIALS AND METHODS: We reviewed children with SMA who were referred for intrathecal nusinersen injections from March to December 2017 at our institution. In select children with spinal hardware, spinal imaging was requested to facilitate pre-procedure planning. Standard equipment for intrathecal injections was utilized. All children were followed up by their referring neurologist.
RESULTS: A total of 104 intrathecal nusinersen injections were performed in 26 children with 100% technical success. Sixty procedures were performed without pre-procedural imaging and via standard interspinous technique. The remaining 44 procedures were performed in 11 complex (i.e. neuromuscular scoliosis or spinal instrumentation) patients requiring pre-procedural imaging for planning purposes. Nineteen of the 44 complex procedures were performed via standard interspinous technique from L2 to S1. Twenty-two of the 44 complex procedures were performed using a neural-foraminal approach from L3 to L5. Three of the 44 complex procedures were performed via cervical puncture technique. There were no immediate or long-term complications but there was one child with short-term complications of meningismus and back pain at the injection site.
CONCLUSION: Although we achieved 100% technical success in intrathecal nusinersen administration, our practices evolved during the course of this study. As a result of our early experience we developed an algorithm to assist in promoting safe and effective nusinersen administration in children with spinal muscular atrophy regardless of SMA type, abnormal spinal anatomy and complex spinal instrumentation.
引用
- Mousa MA, Aria DJ, Schaefer CM, et al. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy. Pediatr Radiol. 2018. PMID: 30022258. doi:10.1007/s00247-018-4206-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。